Arbutus Biopharma Corp Fair Value, Concentration of Risk, Derivative Instruments, Assets
Arbutus Biopharma Corp (ABUS) had Fair Value, Concentration of Risk, Derivative Instruments, Assets of $0 as of 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsAssets · last filed 2015-11-05
- 2015-09-30: Fair Value, Concentration of Risk, Derivative Instruments, Assets $0.00.
| Period end | Fair Value, Concentration of Risk, Derivative Instruments, Assets |
|---|---|
| 2015-09-30 | $0.00 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |